SU1468420A3 - Способ получени производных 3-карбонитрил-5 @ имидазо(1,2- @ )пиридин-6-ил @ -2-оксопиридина или их таутомеров - Google Patents
Способ получени производных 3-карбонитрил-5 @ имидазо(1,2- @ )пиридин-6-ил @ -2-оксопиридина или их таутомеров Download PDFInfo
- Publication number
- SU1468420A3 SU1468420A3 SU864027262A SU4027262A SU1468420A3 SU 1468420 A3 SU1468420 A3 SU 1468420A3 SU 864027262 A SU864027262 A SU 864027262A SU 4027262 A SU4027262 A SU 4027262A SU 1468420 A3 SU1468420 A3 SU 1468420A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- alkyl
- general formula
- compounds
- carbonitrile
- tautomers
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- MVRRNXSBPWPQBL-UHFFFAOYSA-N 3-pyridin-2-yl-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1C1=CC=CC=N1 MVRRNXSBPWPQBL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- -1 C -C-alkyl Chemical group 0.000 claims 1
- 230000003177 cardiotonic effect Effects 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 230000008602 contraction Effects 0.000 abstract description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 abstract 2
- 241000700199 Cavia porcellus Species 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000000304 vasodilatating effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004026 adhesive bonding Methods 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60059450A JPS61218589A (ja) | 1985-03-26 | 1985-03-26 | ５―（６―イミダゾ〔１，２―ａ〕ピリジニル）ピリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1468420A3 true SU1468420A3 (ru) | 1989-03-23 |
Family
ID=13113637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864027262A SU1468420A3 (ru) | 1985-03-26 | 1986-03-25 | Способ получени производных 3-карбонитрил-5 @ имидазо(1,2- @ )пиридин-6-ил @ -2-оксопиридина или их таутомеров |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US4751227A (enExample) |
| EP (1) | EP0199127B1 (enExample) |
| JP (1) | JPS61218589A (enExample) |
| KR (1) | KR930005005B1 (enExample) |
| CN (1) | CN1020608C (enExample) |
| AT (1) | ATE48603T1 (enExample) |
| AU (1) | AU589410B2 (enExample) |
| CA (1) | CA1309718C (enExample) |
| DD (2) | DD283390A5 (enExample) |
| DE (1) | DE3667466D1 (enExample) |
| DK (1) | DK164788C (enExample) |
| ES (5) | ES8706146A1 (enExample) |
| FI (1) | FI86722C (enExample) |
| GR (1) | GR860720B (enExample) |
| HU (1) | HU198045B (enExample) |
| IE (1) | IE59294B1 (enExample) |
| IL (1) | IL78248A (enExample) |
| MX (1) | MX163696B (enExample) |
| NO (1) | NO163490C (enExample) |
| PH (1) | PH22999A (enExample) |
| PT (1) | PT82270B (enExample) |
| SU (1) | SU1468420A3 (enExample) |
| ZA (1) | ZA862259B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2302422C2 (ru) * | 2003-01-09 | 2007-07-10 | Танабе Сейяку Ко., Лтд | Соединения конденсированного фурана |
| RU2420526C2 (ru) * | 2005-04-25 | 2011-06-10 | Новартис Аг | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, КОТОРЫЕ МОЖНО ИСПОЛЬЗОВАТЬ В КАЧЕСТВЕ ИНГИБИТОРОВ ПЕПТИДДЕФОРМИЛАЗЫ (ПДФ) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) * | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| KR920702621A (ko) * | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
| GB9008818D0 (en) * | 1990-04-19 | 1990-06-13 | Ici Plc | Amine derivatives |
| US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| SE9903611D0 (sv) * | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds III |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2011074658A1 (ja) * | 2009-12-18 | 2011-06-23 | 田辺三菱製薬株式会社 | 新規抗血小板薬 |
| CN101830900B (zh) * | 2010-05-27 | 2012-06-06 | 齐鲁制药(海南)有限公司 | 盐酸奥普力农晶型及其制备方法 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| CN102718747B (zh) * | 2012-06-27 | 2014-06-11 | 武汉武药科技有限公司 | 盐酸奥普力农衍生物及其合成方法 |
| CN102702197B (zh) * | 2012-06-27 | 2014-12-03 | 武汉武药科技有限公司 | 盐酸奥普力农衍生物及其制备方法 |
| EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| CA2920856C (en) | 2013-08-09 | 2026-03-03 | Ardelyx, Inc. | Ph modulating compounds for inhibiting gastrointestinal phosphate uptake |
| CN106349246B (zh) * | 2016-08-29 | 2018-10-26 | 山东百诺医药股份有限公司 | 奥普力农及9-氮杂吲哚-5-硼酸的制备方法 |
| CN108840866A (zh) * | 2018-05-24 | 2018-11-20 | 河北宇辰医药科技有限公司 | 一种奥普力农类似物ⅰ的制备方法与用途 |
| CN109575017A (zh) * | 2018-11-01 | 2019-04-05 | 山东蒲济医药科技有限公司 | 一种盐酸奥普力农化合物的制备方法 |
| JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス， インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
| CN111499631B (zh) * | 2020-06-02 | 2021-07-30 | 济南康桥医药科技有限公司 | 一种盐酸奥普力农关键中间体1-咪唑并[1,2-a]吡啶-6-基-2-丙酮的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4105767A (en) * | 1977-03-28 | 1978-08-08 | Merck & Co., Inc. | Imidazo [1,2-a] pyridines substituted with a thienyl, thiazolyl, or thiadiazolyl group |
| ZA81219B (en) * | 1980-01-23 | 1982-01-27 | Schering Corp | Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them |
| EP0068378B1 (en) * | 1981-06-26 | 1986-03-05 | Schering Corporation | Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them |
| DE3406329A1 (de) * | 1984-02-22 | 1985-08-22 | Merck Patent Gmbh, 6100 Darmstadt | Pyridone |
-
1985
- 1985-03-26 JP JP60059450A patent/JPS61218589A/ja active Granted
-
1986
- 1986-03-18 GR GR860720A patent/GR860720B/el unknown
- 1986-03-24 PH PH33568A patent/PH22999A/en unknown
- 1986-03-24 AU AU55072/86A patent/AU589410B2/en not_active Ceased
- 1986-03-24 IL IL78248A patent/IL78248A/xx not_active IP Right Cessation
- 1986-03-25 DE DE8686104064T patent/DE3667466D1/de not_active Expired - Fee Related
- 1986-03-25 DD DD86310251A patent/DD283390A5/de unknown
- 1986-03-25 NO NO861190A patent/NO163490C/no not_active IP Right Cessation
- 1986-03-25 SU SU864027262A patent/SU1468420A3/ru active
- 1986-03-25 AT AT86104064T patent/ATE48603T1/de not_active IP Right Cessation
- 1986-03-25 PT PT82270A patent/PT82270B/pt not_active IP Right Cessation
- 1986-03-25 KR KR1019860002202A patent/KR930005005B1/ko not_active Expired - Fee Related
- 1986-03-25 EP EP86104064A patent/EP0199127B1/en not_active Expired
- 1986-03-25 ES ES553370A patent/ES8706146A1/es not_active Expired
- 1986-03-25 DD DD86288287A patent/DD263057A5/de unknown
- 1986-03-25 HU HU861233A patent/HU198045B/hu not_active IP Right Cessation
- 1986-03-25 FI FI861262A patent/FI86722C/fi not_active IP Right Cessation
- 1986-03-25 IE IE77586A patent/IE59294B1/en not_active IP Right Cessation
- 1986-03-25 MX MX1976A patent/MX163696B/es unknown
- 1986-03-25 CA CA000505040A patent/CA1309718C/en not_active Expired - Fee Related
- 1986-03-25 CN CN86102812A patent/CN1020608C/zh not_active Expired - Lifetime
- 1986-03-25 DK DK137786A patent/DK164788C/da not_active IP Right Cessation
- 1986-03-26 ZA ZA862259A patent/ZA862259B/xx unknown
- 1986-03-26 US US06/844,013 patent/US4751227A/en not_active Expired - Lifetime
- 1986-12-01 ES ES557236A patent/ES8708231A1/es not_active Expired
- 1986-12-01 ES ES557235A patent/ES8708230A1/es not_active Expired
-
1987
- 1987-06-15 ES ES557587A patent/ES8801654A1/es not_active Expired
- 1987-06-15 ES ES557588A patent/ES8801655A1/es not_active Expired
- 1987-08-05 US US07/081,776 patent/US4791203A/en not_active Expired - Lifetime
- 1987-08-05 US US07/081,778 patent/US4791202A/en not_active Expired - Lifetime
- 1987-10-09 US US07/107,473 patent/US4803276A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| Машковский М.Д. Лекарственные средства.-М.г Медицина, 1981, т. i, с. 420. Джоуль Дж., Смит Г. Основы химии гетероциклических соединений.-М.: Мир, 1975, с. 88, 91. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2302422C2 (ru) * | 2003-01-09 | 2007-07-10 | Танабе Сейяку Ко., Лтд | Соединения конденсированного фурана |
| RU2420526C2 (ru) * | 2005-04-25 | 2011-06-10 | Новартис Аг | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, КОТОРЫЕ МОЖНО ИСПОЛЬЗОВАТЬ В КАЧЕСТВЕ ИНГИБИТОРОВ ПЕПТИДДЕФОРМИЛАЗЫ (ПДФ) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Wardener et al. | Effect of sodium intake on ability of human plasma to inhibit renal Na+-K+-adenosine triphosphatase in vitro | |
| US4397854A (en) | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents | |
| Perkins et al. | Renal and cardiac lesions in potassium deficiency due to chronic diarrhea | |
| JP4352613B2 (ja) | 血管新生促進剤及び血管新生作用増強剤 | |
| FI86722C (fi) | Foerfarande foer framstaellning av som laekemedel anvaendbart 5-(6-imidatso/1,2-a/pyridyl)pyridinderivat | |
| US4302471A (en) | Method of treating cardiac and renal failures | |
| JPS6340167B2 (enExample) | ||
| US4968671A (en) | Therapeutic agents for ischemic heart diseases | |
| US4861783A (en) | 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases | |
| SU1470190A3 (ru) | Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила | |
| JP3119738B2 (ja) | Ｎ−フェニル−２−シアノ−３−ヒドロキシクロトンアミド誘導体および免疫調整性を有する医薬品としてのその使用 | |
| Matthay et al. | Grand mal seizure induced by oral theophylline. | |
| Persson et al. | Respiratory and Cardiovascular Effects of 3‐MethyIxanthine, a Metabolite of Theophylline | |
| JPS6043351B2 (ja) | 老人医学的薬剤の製法 | |
| JPS60197672A (ja) | ビリダジノン誘導体またはその塩類 | |
| JPH02502379A (ja) | ５‐シアノ‐プロスタサイクリン誘導体のシクロデキストリンクラスレート化合物、および薬剤としてのその使用 | |
| JPWO1991003471A1 (ja) | アスコルビン酸誘導体 | |
| US4623666A (en) | Pharmacological applications of diphenylhalonium ion | |
| EP0194665A1 (en) | beta-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives | |
| US4418070A (en) | Cardiotonic agents | |
| Adaikan et al. | A comparison of some pharmacological actions of prostaglandin E1, 6-oxo-PGE1 and PGI2 | |
| US4571403A (en) | Antianginal medicated compound | |
| JPS5910571A (ja) | 医薬品として使用可能なピリダジノンの誘導体、及びそれの製造方法 | |
| JPS61289032A (ja) | 強心剤 | |
| CA1184494A (en) | Pharmaceutical composition for treatment of chronic occlusive pulmonary diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a code of a succession state |
Ref country code: RU Ref legal event code: MM4A Effective date: 20040326 |